Intellectual Property
The development work at Cyxone and the research performed by collaborating scientists continues to generate new patent opportunities for the company, and we regularly assess those opportunities.
In order to increase the commercial potential for rabeximod and its attractiveness to potential partners, we have taken measures to expand its market exclusivity period. A number of additional patent applications have recently been filed, and we will continue exploring more options to further expand and strengthen our IP platform.
Rabeximod
| Patent name | Geographies | Status | Expiration date |
|---|---|---|---|
| Alkyl substituted indoloquinoxalines | USA, UK, France, Spain, Germany, Sweden, India, China, Mexico, Japan | Granted | 2025 EU/row 2028 USA |
| New medical use | USA, EU | National Phase | 2041 |
| Rabeximod in treatment in RA | USA, EU, China, Japan, South Korea, Australia, Canada | National Phase | 2041 |
| New oral formulation | USA, EU, China, Japan, South Korea, Australia, Canada | National Phase | 2041 |
| Large scale process | USA, EU, China, Japan, South Korea, Australia, Canada, India | National Phase | 2041 |
| Salt forms of rabeximod | USA | Granted | 2042 |
T20K
| Patent name | Geographies | Satus | Expiration date |
|---|---|---|---|
| Cyclotides as immunosuppressive agents* | USA, Europe, Canada, Australia | Granted | 2032 EU/row/USA + PE |
| Cyclotides in combination with kappa opioid receptor ligands for MS therapy* | Canada, China, EU, Japan, South Korea, USA | National Phase | 2041 |
* Patent is co-owned by the Medical University of Vienna and the University of Freiburg, with Cyxone AB holding an exclusive fully paid-up license